PASG
Passage Bio Inc

751
Loading...
Loading...
News
all
press releases
Wall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a Bet
The mean of analysts' price targets for Passage Bio (PASG) points to a 731% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·21d ago
News Placeholder
More News
News Placeholder
Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade
The mean of analysts' price targets for Passage Bio (PASG) points to a 1415.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·1mo ago
News Placeholder
Analysts' Top Healthcare Picks: Wave Life Sciences (WVE), Passage Bio (PASG)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Wave Life Sciences (WVE Research Report), Passage Bio...
TipRanks Financial Blog·1y ago
News Placeholder
Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program
$10,000 scholarship to be awarded to a rising junior with a life science major attending a Pennsylvania-based four-year college or university Scholarship application deadline is April 26 for the...
Globe Newswire·2y ago
News Placeholder
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
Continued momentum in upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin mutations (GRN) with clinical trial site expansion into Europe and seven...
Globe Newswire·2y ago
News Placeholder
Passage Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative...
Globe Newswire·2y ago
News Placeholder
We're Keeping An Eye On Passage Bio's (NASDAQ:PASG) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St·2y ago
News Placeholder
Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative...
Globe Newswire·2y ago

Latest PASG News

View

Advertisement. Remove ads.

Advertisement. Remove ads.